Phase II trial with temozolomide in children with recurrent high-grade glioma.

Antonio Ruggiero, Cesare Colosimo, Ilaria Lazzareschi, Palma Maurizi, Vita Ridola, Massimo Caldarelli, Concezio Di Rocco, Riccardo Riccardi

Risultato della ricerca: Contributo in rivistaArticolo in rivista

41 Citazioni (Scopus)


PURPOSE: The objective of the study was to evaluate the efficacy and toxicity of Temozolomide (TMZ) administered for 5 consecutive days in three daily dosing in children with recurrent or refractory high-grade glioma. PATIENTS AND METHODS: Twenty-four patients with a median age of 10.5 years were enrolled onto this open-label, multicenter, phase II study. The patients were previously treated with surgical resection (17 of 24), radiotherapy (19 of 24) and chemotherapy (18 of 24). Therapy was administered orally three times a day for 5 consecutive days at the dose of 200 mg/m(2)/dx5 for chemotherapy naive patients. In patients heavily pretreated with chemotherapy the starting dose was of 150 mg/m(2)/dx5. RESULTS: A total of 95 cycles were administered. The median progression free-survival (PFS) was 3 months for the entire group while disease stabilization was obtained in 7 patients (29.1%), all with supratentorial tumors. No CR or PR was observed. TMZ treatment showed a limited toxicity. Thrombocytopenia was the most common hematological adverse effect. Our data suggest a marginal activity of TMZ in children with recurrent high-grade glioma.
Lingua originaleEnglish
pagine (da-a)89-94
Numero di pagine6
RivistaJournal of Neuro-Oncology
Stato di pubblicazionePubblicato - 2005


  • children
  • high-grade glioma
  • temozolomide


Entra nei temi di ricerca di 'Phase II trial with temozolomide in children with recurrent high-grade glioma.'. Insieme formano una fingerprint unica.

Cita questo